CN105456243A - Application of Flabelliferin B in preparing medicine for treating nasopharynx cancer - Google Patents
Application of Flabelliferin B in preparing medicine for treating nasopharynx cancer Download PDFInfo
- Publication number
- CN105456243A CN105456243A CN201510902343.1A CN201510902343A CN105456243A CN 105456243 A CN105456243 A CN 105456243A CN 201510902343 A CN201510902343 A CN 201510902343A CN 105456243 A CN105456243 A CN 105456243A
- Authority
- CN
- China
- Prior art keywords
- flabelliferinb
- flabelliferin
- nasopharyngeal
- application
- nasopharynx cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an application of Flabelliferin B in preparing a medicine for treating nasopharynx cancer, belonging to the technical field of novel applications of medicines. According to the invention, the in-vitro MTT anti-tumor activity evaluation shows that Flabelliferin B has remarkable inhibiting effects for the growth of human nasopharynx cancer cell strains HNE1, HNE2, HONE1 and CNE1. Therefore, Flabelliferin B can be used for preparing the medicine for resisting nasopharynx cancer, and has good development and application prospects. The application of Flabelliferin B in preparing the medicine for treating nasopharynx cancer in the invention is disclosed for the first time, and the inhibiting activity of Flabelliferin B for nasopharynx cancer cells is extremely strong.
Description
Technical field
The present invention relates to the novelty teabag of compound F 17-hydroxy-corticosterone labelliferinB, particularly relate to the application of FlabelliferinB in preparation treatment medicine for nasopharyngeal.
Background technology
Cancer is to one of maximum disease of human life's health hazard, has a large amount of people to die from cancer every year.The research and development of cancer therapy drug are the focuses of study of pharmacy always.74% is had to be natural product or derivatives thereof in antitumor drug, if paclitaxel and derivant thereof are exactly the current reasonable antitumor drug of effect clinically.Therefore, from natural product, anticancer compound is found or lead compound has great importance.
The compound F 17-hydroxy-corticosterone labelliferinB that the present invention relates to is one and delivers (ThusharaDiyabalanage in 2012, etal., FlabelliferinsAandB, SesterterpenoidsfromtheSouthPacificSpongeCarteriospongia flabellifera.J.Nat.Prod.2012, 75, noval chemical compound 1490-1494.), this compound has brand-new framework types (ThusharaDiyabalanage, etal., FlabelliferinsAandB, SesterterpenoidsfromtheSouthPacificSpongeCarteriospongia flabellifera.J.Nat.Prod.2012, 75, 1490-1494.), the purposes of the FlabelliferinB that the present invention relates in preparation treatment medicine for nasopharyngeal is belonged to first public, owing to belonging to brand-new structure type, and its inhibit activities for nasopharyngeal carcinoma cell is unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, control simultaneously for nasopharyngeal carcinoma obviously has significant progress.
Summary of the invention
The object of the invention is to not find that it has the present situation of the report of anti-nasopharyngeal carcinoma activity according in existing FlabelliferinB research, provide the application of FlabelliferinB in the anti-medicine for nasopharyngeal of preparation.
Described compound F 17-hydroxy-corticosterone labelliferinB, structure is as shown in formula I:
The application of described FlabelliferinB in preparation treatment medicine for nasopharyngeal, nasopharyngeal carcinoma cell behaviour nasopharyngeal carcinoma cell line HNE1, HNE2, HONE1 and CNE1.
One treats medicine for nasopharyngeal, and be that active component interpolation adjuvant is prepared from by FlabelliferinB, preparation method, for getting 5 g of compound FlabelliferinB, adds 195 grams, dextrin, and mixing, conventional tablet presses makes 1000.
One treats medicine for nasopharyngeal, and be that active component adds adjuvant and is prepared from by FlabelliferinB, preparation method, for getting 5 g of compound FlabelliferinB, adds starch 195 grams, and mixing, encapsulatedly makes 1000.
The present invention is found by external MTT antineoplastic activity evaluation, FlabelliferinB also has significant inhibitory action to the growth of human nasopharyngeal carcinoma cell line HNE1, HNE2, HONE1 and CNE1, suppresses the IC50 value of this 4 strain Growth of Cells to be respectively 2.15 ± 0.53 μMs, 1.60 ± 0.43 μMs, 1.79 ± 0.53 μMs and 1.89 ± 0.41 μMs.Therefore, FlabelliferinB for the preparation of anti-medicine for nasopharyngeal, can have good development prospect.
The purposes of the FlabelliferinB that the present invention relates in preparation treatment medicine for nasopharyngeal is belonged to first public, because framework types belongs to brand-new framework types, and its inhibit activities for nasopharyngeal carcinoma cell is unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, the control simultaneously for nasopharyngeal carcinoma obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Detailed description of the invention
The preparation method of compound F 17-hydroxy-corticosterone labelliferinB involved in the present invention is see document (ThusharaDiyabalanage, etal., FlabelliferinsAandB, SesterterpenoidsfromtheSouthPacificSpongeCarteriospongia flabellifera.J.Nat.Prod.2012,75,1490-1494.)
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound F 17-hydroxy-corticosterone labelliferinB tablet involved in the present invention:
Get 5 g of compound FlabelliferinB, add 195 grams, dextrin, mixing, conventional tablet presses makes 1000.
Embodiment 2: the preparation of compound F 17-hydroxy-corticosterone labelliferinB capsule involved in the present invention:
Get 5 g of compound FlabelliferinB, add starch 195 grams, mixing, encapsulatedly makes 1000.
Its pharmaceutically active is further illustrated below by pharmacodynamic experiment.
Experimental example: adopt mtt assay assessing compound FlabelliferinB to the growth inhibited effect of human nasopharyngeal carcinoma cell line
1. method: the cell being in growth logarithmic (log) phase: human nasopharyngeal carcinoma cell line HNE1, HNE2, HONE1 and CNE1 (buying from Chinese Academy of Sciences's cell bank) are with 1.5 × 10
4concentration kind is in 96 orifice plates.Original culture medium is sucked after cell culture 24h is adherent.Test is divided into blank group, drug treating group.Blank group changes 1640 culture medium containing 10% hyclone; It is 100 μMs that drug treating group is changed containing concentration, 50 μMs, 10 μMs, 1 μM, 0.1 μM, the culture medium of the FlabelliferinB of 0.01 μM and 0.001 μM.After cultivating 48h, add the MTT of concentration 5mg/mL, continue to be put in CO
2incubator cultivates 4h, then 100 μ L supernatants are sucked along culture fluid top, add 100 μ LDMSO, 10min is placed in dark place, microplate reader (Sunrise Products) is utilized to measure light absorption value (wavelength 570nm), and calculating cell survival according to light absorption value, 6 repeating holes are established in each process.Cell survival rate (%)=Δ OD drug treating/Δ OD blank × 100.
2. the growth of result: FlabelliferinB to human nasopharyngeal carcinoma cell line HNE1, HNE2, HONE1 and CNE1 has significant inhibitory action.This compound suppresses the IC50 value of human nasopharyngeal carcinoma cell line HNE1, HNE2, HONE1 and CNE1 growth to be respectively 2.15 ± 0.53 μMs, 1.60 ± 0.43 μMs, 1.79 ± 0.53 μMs and 1.89 ± 0.41 μMs.
Shown by above-described embodiment, the growth of FlabelliferinB of the present invention to human nasopharyngeal carcinoma cell line HNE1, HNE2, HONE1 and CNE1 has good inhibitory action.Prove thus, it is active that FlabelliferinB of the present invention has anti-nasopharyngeal carcinoma, can for the preparation of anti-medicine for nasopharyngeal.
Claims (4)
- The application of 1.FlabelliferinB in treatment medicine for nasopharyngeal, described compound F 17-hydroxy-corticosterone labelliferinB structure is as shown in formula I:Formula I.
- 2. the application of FlabelliferinB in treatment medicine for nasopharyngeal as claimed in claim 1, is characterized in that nasopharyngeal carcinoma cell behaviour nasopharyngeal carcinoma cell line HNE1, HNE2, HONE1 and CNE1.
- 3. a treatment medicine for nasopharyngeal, it is characterized in that by FlabelliferinB according to claim 1 being that active component interpolation adjuvant is prepared from, preparation method, for getting 5 g of compound FlabelliferinB, adds 195 grams, dextrin, mixing, conventional tablet presses makes 1000.
- 4. a treatment medicine for nasopharyngeal, it is characterized in that by FlabelliferinB according to claim 1 being that active component interpolation adjuvant is prepared from, preparation method, for getting 5 g of compound FlabelliferinB, adds starch 195 grams, mixing, encapsulatedly makes 1000.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510902343.1A CN105456243A (en) | 2015-12-08 | 2015-12-08 | Application of Flabelliferin B in preparing medicine for treating nasopharynx cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510902343.1A CN105456243A (en) | 2015-12-08 | 2015-12-08 | Application of Flabelliferin B in preparing medicine for treating nasopharynx cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105456243A true CN105456243A (en) | 2016-04-06 |
Family
ID=55594710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510902343.1A Pending CN105456243A (en) | 2015-12-08 | 2015-12-08 | Application of Flabelliferin B in preparing medicine for treating nasopharynx cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105456243A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105726547A (en) * | 2016-02-02 | 2016-07-06 | 南京正亮医药科技有限公司 | Application of Flabelliferin B to preparation of medicine for treating breast cancer |
-
2015
- 2015-12-08 CN CN201510902343.1A patent/CN105456243A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105726547A (en) * | 2016-02-02 | 2016-07-06 | 南京正亮医药科技有限公司 | Application of Flabelliferin B to preparation of medicine for treating breast cancer |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105250250A (en) | Application of Nootkatone in preparation of medicine for treating nasopharyngeal carcinoma | |
| CN105456243A (en) | Application of Flabelliferin B in preparing medicine for treating nasopharynx cancer | |
| CN103463046B (en) | The application of Lycojaponicumin A in preparation treatment colorectal cancer medicine | |
| CN105311026A (en) | Application of Leuconoxine in preparation of medicines for treating pancreatic cancer | |
| CN105267221A (en) | Application of Norzoanthamine in preparation of drugs for treating prostate cancer | |
| CN105267193A (en) | Application of Periconianone B to preparation of medicine for treating ovarian cancer | |
| CN103446086B (en) | The application of Incarviatone A in preparation treatment gastric cancer medicament | |
| CN103446143B (en) | The application of Lycojaponicumin C in preparation treatment gastric cancer medicament | |
| CN103463069B (en) | The application of Lycojaponicumin C in preparation treatment medicine for nasopharyngeal | |
| CN103479633B (en) | The application of Lycojaponicumin B in preparation treatment medicine for nasopharyngeal | |
| CN103479632B (en) | The application of Lycojaponicumin B in preparation treatment cervical cancer medicine | |
| CN103494812B (en) | The application of Lycojaponicumin A in preparation treatment ovarian cancer | |
| CN103463034B (en) | The application of Lycojaponicumin B in preparation treatment ovarian cancer | |
| CN103446089B (en) | The application of Incarviatone A in preparation treatment medicine for nasopharyngeal | |
| CN103462966B (en) | The application of Incarviatone A in preparation treatment colorectal cancer medicine | |
| CN103446133B (en) | The application of Lycojaponicumin B in preparation treatment tongue cancer drug | |
| CN103446147B (en) | The application of Lycojaponicumin C in preparation treatment cervical cancer medicine | |
| CN103446091B (en) | The application of Incarviatone A in preparation treatment laryngeal carcinoma medicine | |
| CN103463052B (en) | The application of Lycojaponicumin A in preparation treatment cervical cancer medicine | |
| CN105497016A (en) | Application of Penicillactones A to preparation of drug for treating breast cancer | |
| CN105287482A (en) | Applications of Concrescenins B in preparation of tongue cancer treatment drugs | |
| CN105362260A (en) | Application of Spirooliganone B in preparing medicine for treating tongue cancer | |
| CN105497002A (en) | Application of Perovskone B to preparation of drug for treating tongue cancer | |
| CN105456262A (en) | Application of Melodinine E in preparing medicine for treating endometrial cancer | |
| CN105496989A (en) | Application of Heyneanones A to preparation of drug for treating laryngeal cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160406 |
|
| WD01 | Invention patent application deemed withdrawn after publication |